Investor Deck →
PharmaTher (OTCQB: PHRRF) (CSE: PHRM)
  • HOME
    • About Us
    • Strategic Assets >
      • KETAMINE
      • CEPHARANTHINE
    • CONTACT
  • PERSONALIZ3D™
  • INVESTORS
  • HOME
    • About Us
    • Strategic Assets >
      • KETAMINE
      • CEPHARANTHINE
    • CONTACT
  • PERSONALIZ3D™
  • INVESTORS

Investor Info & News

Presentation →
Fact Sheet →
SEDAR+ →

11/24/2020

PharmaTher Provides Update on its Psychedelic Pharmaceuticals Programs

 

Read More

11/18/2020

PharmaTher Enters Into Research Collaboration with Revive Therapeutics for Psilocybin and panaceAI™ Psychedelic Discovery AI Platform

 

Read More

11/16/2020

PharmaTher Expands Patent Portfolio with Filing of U.S. Patent for Novel Use of Psilocybin to Treat Cancer

 

Read More

11/11/2020

Prolific Parkinson’s Researcher Dr. Alberto J. Espay Joins Pharmather as Scientific Advisor

 

Read More

    Archives

    August 2026
    July 2026
    May 2026
    April 2026
    March 2026
    February 2026
    January 2026
    December 2025
    November 2025
    October 2025
    August 2025
    July 2025
    June 2025
    May 2025
    March 2025
    February 2025
    January 2025
    November 2024
    October 2024
    September 2024
    August 2024
    May 2024
    April 2024
    February 2024
    January 2024
    September 2023
    July 2023
    June 2023
    May 2023
    March 2023
    February 2023
    January 2023
    December 2022
    November 2022
    October 2022
    September 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020

Sign Up for Press Releases
Sign Up →

Follow Us

Contact Us →
Psychedelic Pharmaceuticals
OTCQB: PHRRF | CSE:PHRM
© COPYRIGHT 2026.  PharmaTher Holdings Ltd.   ALL RIGHTS RESERVED.
"The product candidates described on this website are investigational and have not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. Safety and efficacy have not been established."